Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced the initiation of a research collaboration with Merck, through a subsidiary. The collaboration will focus on screening for biased ligands against an undisclosed receptor using Trevena's proprietary assays and know-how. "We are delighted to work with Merck’s scientists to expand their understanding of the signaling pathways of the selected receptor," stated Maxine Gowen, Trevena's CEO. Financial details of the collaboration have not been disclosed.
Copyright © Trevena, Inc.